Investors sentiment increased to 1.03 in Q3 2017. Its up 0.08, from 0.95 in 2017Q2. It is positive, as 62 investors sold BMY shares while 519 reduced holdings. 137 funds opened positions while 460 raised stakes. 1.11 billion shares or 0.68% more from 1.10 billion shares in 2017Q2 were reported.
Lumina Fund Mngmt Lc accumulated 107,200 shares. Howland Capital Ltd Liability Co reported 0.22% stake. Gideon Advisors reported 3,379 shares. Moneta Gp Investment Advisors Ltd Liability owns 4,128 shares or 0.04% of their US portfolio. Legal General Grp Inc Public Ltd Company owns 8.62 million shares for 0.41% of their portfolio.
Advisor Ptnrs Ltd Liability Com accumulated 36,961 shares. Northstar Gp Incorporated, a New York-based fund reported 7,541 shares. Bessemer Inc has 1.78M shares. Livingston Asset Mngmt Company (Operating As Southport Management) holds 0.19% or 6,937 shares in its portfolio.
Bryn Mawr Tru Com holds 0.54% or 150,096 shares. Whitnell Company has invested 0.65% in Bristol-Myers Squibb Company (NYSE:BMY). Donaldson Capital Mgmt Limited Company stated it has 13,824 shares. First Allied Advisory Inc accumulated 75,813 shares. Wealthtrust Fairport Limited Company accumulated 6,377 shares. Cobblestone Capital Ltd Liability Corp Ny reported 16,913 shares.
Since September 6, 2017, it had 1 insider buy, and 2 sales for $646,385 activity. On Wednesday, September 6 the insider Caldarella Joseph C sold $560,400. 5,300 shares were sold by Lynch Thomas J. Jr., worth $335,172 on Tuesday, December 12.
Sessa Capital Im Lp decreased its stake in Bristol Myers Squibb Co (BMY) by 95.58% based on its latest 2017Q3 regulatory filing with the SEC. Sessa Capital Im Lp sold 4.33 million shares as the company’s stock declined 1.04% while stock markets rallied. The institutional investor held 200,000 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $12.75 million, down from 4.53M at the end of the previous reported quarter.
Sessa Capital Im Lp who had been investing in Bristol Myers Squibb Co for a number of months, seems to be less bullish one the $108.03B market cap company. The stock increased 0.73% or $0.48 during the last trading session, reaching $66.17. About 5.39M shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has declined 23.19% since March 4, 2017 and is downtrending. It has underperformed by 39.89% the S&P500.
Analysts await Bristol-Myers Squibb Company (NYSE:BMY) to report earnings on April, 26. They expect $0.87 earnings per share, up 3.57 % or $0.03 from last year’s $0.84 per share. BMY’s profit will be $1.42B for 19.01 P/E if the $0.87 EPS becomes a reality. After $0.68 actual earnings per share reported by Bristol-Myers Squibb Company for the previous quarter, Wall Street now forecasts 27.94 % EPS growth.
More notable recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: Bloomberg.com which released: “Nektar Gets a Payday But No Mega-Buyout” on February 14, 2018, also Seekingalpha.com with their article: “Nektar Therapeutics: What The Bristol-Myers Squibb Deal For NKTR-214 Entails” published on February 15, 2018, Investorplace.com published: “At $65.63, Bristol-Myers Squibb Co (BMY) a Buy” on March 02, 2018.
More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) were released by: Fool.com and their article: “Can Bristol-Myers Squibb Squeeze $3.6 Billion From Its Nektar Therapeutics Deal?” published on February 20, 2018 as well as Seekingalpha.com‘s news article titled: “Bristol-Myers Squibb Makes Enormous Advance In First-Line Lung Cancer” with publication date: February 06, 2018.
Bristol-Myers Squibb Company (NYSE:BMY) Ratings Coverage
Among 20 analysts covering Bristol-Myers Squibb Company , 7 have Buy rating, 3 Sell and 10 Hold. Therefore 35% are positive. Bristol-Myers Squibb Company had 75 analyst reports since July 28, 2015 according to SRatingsIntel. The stock has “Buy” rating by UBS on Tuesday, September 29. On Thursday, October 26 the stock rating was maintained by Piper Jaffray with “Hold”. The rating was downgraded by Morgan Stanley to “Equal-Weight” on Friday, August 5.
The firm has “Hold” rating given on Tuesday, June 14 by Jefferies. BMO Capital Markets maintained it with “Sell” rating and $49.0 target in Wednesday, August 16 report. The stock of Bristol-Myers Squibb Company (NYSE:BMY) has “Sell” rating given on Monday, June 5 by BMO Capital Markets. The company was maintained on Monday, November 13 by BMO Capital Markets. The rating was maintained by Barclays Capital on Friday, October 13 with “Equal-Weight”.